Publications by authors named "C J Hana"
Article Synopsis
- Next-generation sequencing (NGS) has revealed numerous genetic mutations that are critical for understanding cancer, particularly focusing on isocitrate dehydrogenase (IDH) enzymes.
- IDH exists in different forms (IDH1 in the cytosol and IDH2/IDH3 in mitochondria) and is crucial for metabolic processes such as converting isocitrate into α-ketoglutarate, affecting cellular functions like gene regulation and tissue health.
- Mutations in the IDH genes are linked to several cancers, including gliomas and acute myeloid leukemia, prompting exploration of IDH inhibitors as potential therapeutic options.
Claudins are a family of 27 proteins that have an important role in the formation of tight junctions. They also have an important function in ion exchange, cell mobility, and the epithelial-to-mesenchymal transition, the latter being very important in cancer invasion and metastasis. Therapeutic targeting of claudins has been investigated to improve cancer outcomes.
View Article and Find Full Text PDFBackground: Various SARS-CoV-2 variants of concerns (VOCs) characterized by higher transmissibility and immune evasion have emerged. Despite reduced vaccine efficacy against VOCs, currently available vaccines provide protection. Population-based evidence on the humoral immune response after booster vaccination is crucial to guide future vaccination strategies and in preparation for imminent COVID-19 waves.
View Article and Find Full Text PDFIn the realm of cancer therapeutics, targeting the hypoxia-inducible factor (HIF) pathway has emerged as a promising strategy. This study delves into the intricate web of HIF-associated mechanisms, exploring avenues for future anticancer therapies. Framing the investigation within the broader context of cancer progression and hypoxia response, this article aims to decipher the pivotal role played by HIF in regulating genes influencing angiogenesis, cell proliferation, and glucose metabolism.
View Article and Find Full Text PDFArticle Synopsis
- Acute myeloid leukemia (AML) outcomes are influenced by genetic factors, with NPM1 mutations found in about 30% of cases and linked to a better prognosis.
- This study involving 233 AML patients showed that those with secondary mutations (sMut) had significantly lower overall survival rates compared to those without sMut, even when considering favorable-risk AML.
- Among patients who achieved measurable residual disease negativity, those with sMut still had poorer survival compared to MRD negative patients, highlighting the adverse impact of sMut on prognosis in AML.